Spiriva [tiotropium bromide] 18g Once Daily in Chinese COPD [chronic obstructive pulmonary disease] Patients of Different Disease Severities

Trial Profile

Spiriva [tiotropium bromide] 18g Once Daily in Chinese COPD [chronic obstructive pulmonary disease] Patients of Different Disease Severities

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Jun 2014

At a glance

  • Drugs Tiotropium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 19 May 2010 Actual patient number (4918) added as reported by ClinicalTrials.gov.
    • 15 Apr 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top